

North Central Cancer Treatment Group

N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR® Depot) for Symptomatic Ascites in Cancer Patients

Status Change – March 30, 2007

NOTICE OF STATUS CHANGE

This study is temporarily suspended to patient accrual effective Friday, March 30, 2007.

Patient entry will not be allowed after 4:30 p.m. Thursday, March 29, 2007 until further notification is issued.

The placebo for this study currently expires on March 31, 2007. An addendum will be forthcoming once a new placebo becomes available.

Please retain this notice with the protocol.